[{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"d557545c-a8fc-4f7f-9d63-eb284cbe8b60","acronym":"AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864","created_at":"2023-02-14T18:02:24.073Z","updated_at":"2024-07-02T16:35:05.951Z","phase":"Phase 1/2","brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","source_id_and_acronym":"NCT05726864 - AMPLIFY-7P","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"a0f9dd51-d692-4574-b05e-3f5caa78cfd2","acronym":"AMPLIFY-201","url":"https://clinicaltrials.gov/study/NCT04853017","created_at":"2021-04-21T11:53:35.333Z","updated_at":"2024-07-02T16:35:09.637Z","phase":"Phase 1","brief_title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","source_id_and_acronym":"NCT04853017 - AMPLIFY-201","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P • Promune (agatolimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-15"},{"id":"5cdbdbf3-e8da-4789-91ba-999fa7089d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454035","created_at":"2021-01-18T17:01:52.689Z","updated_at":"2024-07-02T16:35:22.023Z","phase":"Phase 1","brief_title":"Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","source_id_and_acronym":"NCT03454035","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61","tags":["KRAS • BRAF • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 04/24/2026","study_completion_date":" 04/24/2026","last_update_posted":"2024-01-26"},{"id":"4c8ef224-f9fb-4c0f-9c53-755646bf66ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04109456","created_at":"2022-11-22T16:57:30.683Z","updated_at":"2024-07-02T16:35:24.033Z","phase":"Phase 1","brief_title":"IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma","source_id_and_acronym":"NCT04109456","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-10"},{"id":"754f31b9-2621-4d8e-805c-acb364907f2f","acronym":"GO-005","url":"https://clinicaltrials.gov/study/NCT03953235","created_at":"2021-01-18T19:27:25.774Z","updated_at":"2025-02-25T14:28:22.357Z","phase":"Phase 1/2","brief_title":"A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens","source_id_and_acronym":"NCT03953235 - GO-005","lead_sponsor":"Gritstone bio, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 07/18/2019","start_date":" 07/18/2019","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 03/10/2023","study_completion_date":" 03/10/2023","last_update_posted":"2023-09-13"},{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"}]